We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $791M
1-Year Est. Return 245.83%
This Fund
S&P 500
This Quarter Est. Return
+77.63%
1 Year Est. Return
+245.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$581M
AUM Growth
+$190M
Cap. Flow
-$9.39M
Cap. Flow %
-1.62%
Top 10 Hldgs %
39.55%
Holding
201
New
71
Increased
49
Reduced
24
Closed
56

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$13.1M
2
CORT icon
Corcept Therapeutics
CORT
+$7.65M
3
VKTX icon
Viking Therapeutics
VKTX
+$5.07M
4
UTHR icon
United Therapeutics
UTHR
+$4.66M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.59M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.5M
2
PCVX icon
Vaxcyte
PCVX
+$8.74M
3
SLNO
Soleno Therapeutics
SLNO
+$8.25M
4
INDV icon
Indivior Pharmaceuticals
INDV
+$7.23M
5
BMY icon
Bristol-Myers Squibb
BMY
+$5.86M

Sector Composition

Rank Sector Weight
1 Miscellaneous 71.08%
2 Healthcare 28.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
1
CALL
Vertex Pharmaceuticals
VRTX
$138B
$40M 6.9%
+88,300
New +$38.1M
XBI icon
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.7B
$30.5M 5.25%
+250,000
New +$28.7M
PRAX icon
3
PUT
Praxis Precision Medicines
PRAX
$9.82B
$29.7M 5.11%
100,600
+600
+0.6% +$112K
VKTX icon
4
CALL
Viking Therapeutics
VKTX
$4.07B
$24.2M 4.17%
688,900
+283,800
+70% +$10.1M
RNAM
5
CALL
DELISTED
Avidity Biosciences
RNAM
$23.7M 4.08%
328,000
+127,900
+64% +$8.26M
QQQ icon
6
PUT
Invesco QQQ Trust
QQQ
$489B
$18.4M 3.17%
+30,000
New +$18.4M
JAZZ icon
7
CALL
Jazz Pharmaceuticals
JAZZ
$16B
$17.9M 3.08%
105,300
+5,300
+5% +$813K
APGE
8
CALL
DELISTED
Apogee Therapeutics
APGE
$15.9M 2.74%
211,100
+83,700
+66% +$5.27M
BBIO icon
9
PUT
BridgeBio Pharma
BBIO
$14.6B
$15.3M 2.64%
+200,000
New +$13.1M
TERN
10
DELISTED
Terns Pharmaceuticals
TERN
$14M 2.41%
345,880
+22,721
+7% +$525K
JNJ icon
11
Johnson & Johnson
JNJ
$663B
$13.8M 2.37%
+66,444
New +$13.1M
GPCR icon
12
CALL
Structure Therapeutics
GPCR
$3.38B
$13.3M 2.3%
+191,700
New +$7.83M
VKTX icon
13
Viking Therapeutics
VKTX
$4.07B
$11.9M 2.04%
336,849
+143,160
+74% +$5.07M
VKTX icon
14
PUT
Viking Therapeutics
VKTX
$4.07B
$11.1M 1.92%
+316,700
New +$11.2M
BBIO icon
15
CALL
BridgeBio Pharma
BBIO
$14.6B
$10.7M 1.84%
139,600
+8,200
+6% +$538K
JNJ icon
16
CALL
Johnson & Johnson
JNJ
$663B
$10.3M 1.78%
+50,000
New +$9.89M
ABVX
17
Abivax
ABVX
$10B
$10.2M 1.76%
75,644
+34,024
+82% +$3.71M
INCY icon
18
PUT
Incyte
INCY
$25.7B
$9.88M 1.7%
+100,000
New +$9.68M
INSM icon
19
CALL
Insmed
INSM
$27.6B
$9.19M 1.58%
+52,800
New +$9.63M
CAPR icon
20
CALL
Capricor Therapeutics
CAPR
$547M
$9.01M 1.55%
312,300
+12,300
+4% +$161K
BMRN icon
21
BioMarin Pharmaceuticals
BMRN
$12.9B
$8.7M 1.5%
146,361
-66,516
-31% -$3.62M
IONS icon
22
CALL
Ionis Pharmaceuticals
IONS
$9.65B
$8.4M 1.45%
106,200
+6,200
+6% +$467K
REGN icon
23
Regeneron Pharmaceuticals
REGN
$85.2B
$7.95M 1.37%
10,300
-19,860
-66% -$13.5M
INDV icon
24
CALL
Indivior Pharmaceuticals
INDV
$4.12B
$7.9M 1.36%
+220,300
New +$6.73M
QURE icon
25
PUT
uniQure
QURE
$3.09B
$7.22M 1.24%
301,800
+1,800
+0.6% +$69.5K
1
2 3 4 5

Similar funds

KAS
Kemnay Advisory Services New York $791M AUM 14.14% 1-Year Est. Return
FSAG
Financial Solutions Advisory Group Chicago, Illinois $791M AUM
KAS
KPP Advisory Services Louisville, Kentucky $791M AUM 28.5% 1-Year Est. Return
BSSFA
Baron Silver Stevens Financial Advisors Boca Raton, Florida $791M AUM 18.81% 1-Year Est. Return
GUB
Golden Unicorn BVI Road Town $792M AUM 60.81% 1-Year Est. Return
EA
Enclave Advisors Austin, Texas $790M AUM 21.99% 1-Year Est. Return
BBES
Buffalo Business & Estate Services Orchard Park, New York $793M AUM
GEA
Glen Eagle Advisors Kingston, New Jersey $793M AUM 21.06% 1-Year Est. Return

Diadema Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Diadema Partners held 201 positions worth $581M, up 48% from $391M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Diadema Partners's Q4 2025 filing shows 71 new, 49 increased, 24 reduced and 56 closed positions. Its largest new stake was Johnson & Johnson: 66,444 shares worth $13.8M. The largest sale was Regeneron Pharmaceuticals, an estimated $13.5M.

By sector, the portfolio is most concentrated in Miscellaneous at 71% of assets, up from 63% a quarter earlier, followed by Healthcare.

  • Diadema Partners's largest Q4 2025 buy was Johnson & Johnson: 66,444 shares worth $13.8M.
  • Diadema Partners added most to Viking Therapeutics in Q4 2025, an estimated $5.07M increase.
  • Diadema Partners's biggest Q4 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $13.5M.
  • Diadema Partners fully exited Bristol-Myers Squibb in Q4 2025, selling an estimated $5.86M.
  • Diadema Partners's ten largest holdings make up 40% of its $581M portfolio in Q4 2025.
  • Diadema Partners opened 71 new positions and closed 56 in Q4 2025.
  • Diadema Partners's portfolio value rose 48% quarter-over-quarter to $581M.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.